NCT06334575View on ClinicalTrials.gov

Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels

PHASE4RecruitingINTERVENTIONAL
Enrollment

135

Participants

Timeline

Start Date

February 12, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Budesonide

receive, on top of their usual treatment Budesonide dry powder inhaler, 400 mcg/12 hours for 8 weeks

Trial Locations (6)

Unknown

NOT_YET_RECRUITING

Philips University of Marburg, Marburg

NOT_YET_RECRUITING

Academisch Ziekenhuis Groningen, Groningen

NOT_YET_RECRUITING

University of Leicester, Leicester

NOT_YET_RECRUITING

Imperial College London, London

08036

RECRUITING

Clínic Barcelona, Barcelona

07120

NOT_YET_RECRUITING

Son Espases, Palma de Mallorca

All Listed Sponsors
lead

Maria Joyera Rodríguez

OTHER

NCT06334575 - Molecular Signatures Associated With Response to ICS Treatment in Patients With COPD Stratified by Eosinophil Levels | Biotech Hunter | Biotech Hunter